Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis

Nature Medicine

Volumn 10, Issue 11, 2004, Pages 1216-1221

  Wang, Hong ^a   Liao, Hong ^a   Ochani, Mahendar ^a   Justiniani, Marilou ^a   Lin, Xinchun ^a   Yang, Lihong ^a   Al Abed, Yousef ^a   Wang, Haichao ^a   Metz, Christine ^a   Miller, Edmund J ^a   Tracey, Kevin J ^a   Ulloa, Luis ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE ACTIVATION; HORMONE ACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SEPSIS; SURVIVAL;

ACETYLCHOLINE; ANIMALS; CECUM; FLUORESCENT ANTIBODY TECHNIQUE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NEUROIMMUNOMODULATION; NICOTINE; OLIGONUCLEOTIDES; RECEPTORS, NICOTINIC; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 9144263639     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1124     Document Type: Article

References (46)

1. Sands, K.E. et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 278, 234-240 (1997).
2. Angus, D.C. et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 163, 1389-1394 (2001).
3. Marshall, J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit. Care Med. 29, S99-S106 (2001).
4. Friedman, G., Silva, E. & Vincent, J.L. Has the mortality of septic shock changed with time. Crit. Care Med. 26, 2078-2086 (1998).
5. Czura, C.J. et al. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv. Immunol. 84, 181-200 (2004).
6. Tracey, K.J. et al. Anti-cachectin/tnf monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664 (1987).
7. Dinarello, CA. The interleukin-1 family: 10 years of discovery. FASEB J. 8, 1314-1325 (1994).
8. Dinarello, C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 4, 378-385 (2004).
9. Riedemann, N.C., Guo, R.F. & Ward, P.A. Novel strategies for the treatment of sepsis. Nat. Med. 9, 517-524 (2003).
10. Scaffidi, P., Misteli, T. & Bianchi, M.E. Release of chromatin protein hmgb1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
11. Abraham, E. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Norasept ii study group. Lancet 351, 929-933 (1998).
12. Abraham, E., et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock, A randomized, double-blind, placebo-controlled, multicenter phase iii trial with 1,342 patients. Crit. Care Med. 29, 503-510 (2001).
13. Fisher, C.J. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase iii rhil-1ra sepsis syndrome study group. JAMA 271, 1836-1843 (1994).
14. Eskandari, M.K. et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148, 2724-2730 (1992).
15. Wang, H. et al. Hmg-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
16. Andersson, U., et al. High mobility group 1 protein (hmg-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565-570 (2000).
17. Ulloa, L. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351-12356 (2002).
18. Bustin, M. At the crossroads of necrosis and apoptosis, signaling to multiple cellular targets by HMGB1. Sci STKE 151 (2002).
19. Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101, 296-301 (2004).
20. Bonaldi, T. et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560.
21. Li, J. et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9, 37-45 (2003).
22. Borovikova, L.V. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405, 458-462 (2000).
23. Bernik, T.R. et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 195, 781-788 (2002).
24. Tracey, K.J. The inflammatory reflex. Nature 420, 853-859 (2002).
25. Wang, H. et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384-388 (2003).
26. Rendon-Mitchell, B. et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 170, 3890-3897 (2003).
27. Lee, J.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
28. Derijard, B. et al. Independent human map-kinase signal transduction pathways defined by mek and mkk isoforms. Science 267, 682-685 (1995).
29. Baeuerle, P.A. & Henkel, T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12, 141-179 (1994).
30. Li, Q. & Verma, I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
31. Wang, H., Czura, C. & Tracey, K.J. Lipid unites disparate syndromes of sepsis. Nat. Med. 10, 124-125 (2004).
32. Karlin, A. Emerging structure of the nicotinic acetylcholine receptors. Nat. Rev. Neurosci. 3, 102-114 (2002).
33. Wess, J. Muscarinic acetylcholine receptor knockout mice, novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 44, 423-450 (2004).
34. Unwin, N. Acetylcholine receptor channel imaged in the open state. Nature 373, 37-43 (1995).
35. Hogg, R.C., Raggenbass, M. & Bertrand, D. Nicotinic acetylcholine receptors, from structure to brain function. Rev. Physiol. Biochem. Pharmacol. 147, 1-46 (2003).
36. Ando, Y. Transdermal nicotine for ulcerative colitis. Ann. Intern. Med. 127, 491-492 (1997).
37. Guarini, S. et al. Efferent vagal fibre stimulation blunts nuclear factor-κB activation and protects against hypovolemic hemorrhagic shock. Circulation 107, 1189-1194 (2003).
38. Ulloa, L. Batliwalla, F.M., Andersson, U., Gregersen, P.K. & Tracey, K.J. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 48, 876-881 (2003).
39. Andersson, U. & Erlandsson-Harris, H. Hmgb1 is a potent trigger of arthritis. J. Intern. Med. 255, 344-350 (2004).
40. Jick, H. & Walker, A.M. Cigarette smoking and ulcerative colitis. N. Engl. J. Med. 308, 261-263 (1983).
41. Rampton, D.S. Smoking and ulcerative colitis. Lancet 1, 168 (1984).
42. Martin, T.R. MIF mediation of sepsis. Nat. Med. 6, 140-141 (2000).
43. Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6, 164-170 (2000).
44. Yan, J. et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 10, 161-167 (2004).
45. Ulloa, L., Diaz-Nido, J. & Avila, J. Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells. EMBO J. 12, 1633-1640 (1993).
46. Ulloa, L. et al. Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway. Nature 397, 710-713 (1999).